Navigation Links
BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
Date:3/16/2010

HepaSphere™ doxorubicin delivery embolotherapy microspheres are effective in treating liver cancer, hepatocellular cancer (HCC). BioSphere Medical’s microspheres for drug delivery transarterial chemoembolization (TACE) were the subject of a clinical study presentation at the Society of Interventional Radiology (SIR) annual meeting.

(PRWEB) March 16, 2010 -- BioSphere Medical, Inc. (NASDAQ: BSMD), announced that its doxorubicin delivery embolotherapy microspheres HepaSphere™ were featured in a scientific session on the advances in minimally invasive treatments for liver cancer, at the Society of Interventional Radiology (SIR) 35th Annual Meeting, in Tampa, FL. Opening the session on transarterial chemoembolization (TACE) for liver cancer, Geert Maleux, M.D., Ph.D., an interventional radiologist at the University Hospitals Leuven, Belgium, presented the results of the first prospective, randomized clinical study demonstrating the effectiveness of HepaSphere™ to treat patients with hepatocellular cancer (HCC), the most common form of liver cancer.

Dr. Maleux’s study, conducted in Belgium, demonstrated the safety of HepaSphere™ drug delivery chemoembolization (hqTACE). Patients treated with HepaSphere™, compared to patients who received conventional transarterial chemoembolization (cTACE), had lower circulating levels of doxorubicin, which significantly reduced drug toxicity and serious side effects. The hqTACE patients also had better preserved liver function.

Today’s presentation spotlights the significant advances achieved by the company in liver cancer treatment. BioSphere has submitted an Investigational Device Exemption (IDE) application to the U.S. FDA for QuadraSphere® Microspheres for a phase III clinical trial. If approved, it will be the first phase III clinical trial for chemoembolization of primary liver cancer in the United States.    

HepaSphere™ Microspheres, however, have been CE marked in the European Union since 2007 for embolization of liver cancer and hepatic metastases, with or without delivery of doxorubicin. In the United States, QuadraSphere® is cleared by the FDA for embolization of hypervascularized tumors and peripheral arteriovenous malformations.

Surgical removal is not possible for more than two-thirds of primary liver cancer patients and 90 percent of patients with secondary liver cancer. According to the U.S. National Cancer Institute (NCI), no standard treatment currently exists for liver cancer when tumors cannot be surgically removed and liver transplantation is not a viable option.

In a related presentation, Diane K. Reyes, Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, presented results of a Phase II two-year, single-arm clinical study that treated patients with unresectable liver cancer with bevacizumab (Avastin®) and conventional TACE (cTACE) using Embosphere® Microspheres. This pilot study evaluated tumor response and safety of liver chemoembolization combined with an antiangiogenic drug that works by preventing new blood vessel growth. The data showed treatment was well tolerated, with progression-free survival of 16 months.

BioSphere Medical, Inc. (NASDAQ:BSMD) is a medical device company that develops and manufactures bioengineered microspheres for use in embolotherapy, which is the minimally invasive treatment of tumors and vascular malformations by inhibiting blood flow. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with properties that may be beneficial in a variety of medical applications. Most notably, the company was a pioneer in uterine fibroid embolization (UFE) when it launched the first approved embolic microsphere for UFE. The Company has a dominant worldwide position in UFE embolics and has developed microspheres for use in interventional oncology. BioSphere is expanding its clinical research on the use of its microspheres in liver cancer chemoembolization and other disease states. For more information, consult the company’s website at http://www.biospheremed.com/index.cfm

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company’s planned HepaSphere™/QuadraSphere® in Liver Cancer Treatment clinical trial, the expected benefits of HepaSphere and QuadraSphere for the treatment of liver cancer, and the effectiveness of HepaSphere™/QuadraSphere® to deliver the chemotherapeutic drug doxorubicin in patients with hepatocellular cancer; and treatment benefits of Embosphere® and bevacizumab in liver cancer. The Company may use words such as "plans," "seeks," "projects," "believes," "may," "anticipates," "estimates," "should," "intends," "looking forward," and similar expressions to identify these forward-looking statements. These statements are subject to risks and uncertainties and are based upon the Company's beliefs and assumptions. There are a number of important factors that may affect the Company's actual performance and results and the accuracy of its forward-looking statements, many of which are beyond the Company's control and are difficult to predict. These and other risk factors are discussed under “Risk Factors” and elsewhere in BioSphere Medical, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2008, in its Quarterly Report on Form 10-Q for the quarter ended December 31, 2009 and other filings that the Company makes from time to time with the U.S. Securities and Exchange Commission (SEC). BioSphere Medical, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

###

Read the full story at http://www.prweb.com/releases/livercancerembolization/SIR/prweb3465204.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
2. Renowned Medical Tourism Industry Expert and Author Josef D. Woodman Joins Satori World Medical's Strategic Advisory Board
3. Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board
4. Novasys Medical's Debra Reisenthel Named ABL's 2010 “Leadership in Innovation” Awardee
5. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
6. Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres
7. Scientific Paper Supports Micro-Bland Embolization Technique for Liver Cancer With Embozene(TM) Microspheres
8. Safe Crossing Week 2007 Teaches Kids How to Behave Safely Around Trains
9. Federal Regulation Will Require Renovators to Work Safely with Lead-Paint
10. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
11. Allergic-like reactions to iodinated contrast material treated safely with commonly used medications
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The Dog ... dog who lives his life to the fullest, as God intended. “The Adventures of ... Holmgren, a mother and grandmother pursuing her passion for writing, especially about truth and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... pipeline is very strong with a total of 97 drug candidates. Pharma ... Sanofi are involved in the development of the IPF therapeutics. The IPF ... III stage, 15 are in Phase II stage, 12 are in Phase ...
Breaking Medicine Technology: